The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection

Patient Preference and Adherence

Volumn 9, Issue , 2015, Pages 923-942

  Jin, Jing Fen ^a   Zhu, Ling Ling ^a   Chen, Meng ^a   Xu, Hui Min ^a   Wang, Hua Fen ^a   Feng, Xiu Qin ^a   Zhu, Xiu Ping ^a   Zhou, Quan ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Administration route; Dosage and administration; Efficacy; Medication safety; Patient preference; Pharmacoeconomic

Indexed keywords

ABATACEPT; ADRENALIN; ANTIBIOTIC AGENT; ASPARAGINASE MACROGOL; BETA1A INTERFERON; BORTEZOMIB; CEFTRIAXONE; CHORIONIC GONADOTROPIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; HEPATITIS B ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN; INSULIN; KETAMINE; METHOTREXATE; MORPHINE; OPIATE; PHYTOMENADIONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TRASTUZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; VENOM ANTISERUM;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ANAPHYLAXIS; BODY MASS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GENDER; HEALTH STATUS; HEPATITIS B; HUMAN; MEDICATION THERAPY MANAGEMENT; MULTIPLE SCLEROSIS; PATIENT ATTITUDE; PATIENT PREFERENCE; PHARMACOECONOMICS; REVIEW; RHEUMATIC DISEASE; SOCIOECONOMICS;

EID: 84936953307     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S87271     Document Type: Review

References (111)

1. Injection (Medicine)-WIKIPEDIA, The Free Encyclopedia. [webpage on the Internet] Available from: http://en. wikipedia. org/wiki/Injection_(medicine). [updated 2015 March 5]. Accessed March 29, 2015.
2. Pharmaceutical drug use principle issued. National Health and Family Planning Commission of China. December 11 2013. Available from: http://news. xinhuanet. com/english/china/2013-12/11/c_132959145. htm. Accessed June 29, 2015.
3. Plumb B, Bright P, Gompels MM, Unsworth DJ. Correct recognition and management of anaphylaxis: not much change over a decade. Postgrad Med J. 2015; 91: 3-7.
4. Gabriel J. Intravenous versus subcutaneous access for palliative care patients. Br J Nurs. 2014; 23: S20-S22.
5. Stoner KL, Harder H, Fallowfield LJ, Jenkins VA. Intravenous versus subcutaneous drug administration. which do patients prefer? a systematic review. Patient. Epub 2014 July 12.
6. Reggia R, Franceschini F, Tincani A, Cavazzana I. Switching from intravenous to subcutaneous formulation of abatacept: a single-center Italian experience on efficacy and safety. J Rheumatol. 2015; 42: 193-195.
7. Dychter SS, Gold DA, Haller MF. Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. J Infus Nurs. 2012; 35: 154-160.
8. Herceptin. [webpage on the Internet] Available from: http://www. rxlist. com/herceptin-drug/indications-dosage. htm. [updated 2013 May 12]. Accessed March 29, 2015.
9. Sanford M. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer. Target Oncol. 2014; 9: 85-94.
10. Pivot X, Gligorov J, Müller V, et al; PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014; 25: 1979-1987.
11. Pivot X, Gligorov J, Müller V, et al; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013; 14: 962-970.
12. Jackisch C, Kim SB, Semiglazov V, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015; 26: 320-325.
13. RITUXAN. [webpage on the Internet] Available from: http://www. rxlist. com/rituxan-drug/indications-dosage. htm. [updated 2013 October 21]. Accessed March 29, 2015.
14. Salar A, Avivi I, Bittner B, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014; 32: 1782-1791.
15. Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014; 17: 459-468.
16. Kagan L, Turner MR, Balu-Iyer SV, Mager DE. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res. 2012; 29: 490-499.
17. Doyle MK, Rahman MU, Frederick B, et al. Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial. Rheumatology (Oxford). 2013; 52: 1214-1219.
18. Sylwestrzak G, Liu J, Stephenson JJ, Ruggieri AP, DeVries A. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits. 2014; 7: 71-81.
19. Scarpato S, Antivalle M, Favalli EG, et al; RIVIERA co-authors. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010; 49: 289-294.
20. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011; 12: 431-440.
21. Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012; 51: 823-829.
22. Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012; 97: 1925-1928.
23. Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother. 2013; 47: 1136-1142.
24. Kamimura T, Miyamoto T, Yokota N, Aoki T, Ito Y, Akashi K. High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. Int J Hematol. 2013; 98: 694-701.
25. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015; 100(5): e207-e210.
26. Ethyol. [webpage on the Internet] Available from: http://www. rxlist. com/ethyol-drug. htm. [updated 2008 August 18]. Accessed March 29, 2015.
27. Bardet E, Martin L, Calais G, et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC 2000-2002 phase III randomized trial. J Clin Oncol. 2011; 29: 127-133.
28. Koukourakis MI, Simopoulos C, Minopoulos G, et al. Amifostine before chemotherapy: improved tolerance profile of the subcutaneous over the intravenous route. Clin Cancer Res. 2003; 9: 3288-3293.
29. Bardet E, Martin L, Calais G, et al. Preliminary data of the GORTEC 2000-2002 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 2002; 29(6 suppl 19): 57-60.
30. Rosenfeld CS, Sulecki M, Evans C, Shadduck RK. Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia. Exp Hematol. 1991; 19: 273-277.
31. Lieschke GJ, Maher D, O'Connor M, et al. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res. 1990; 50: 606-614.
32. Paul M, Ram R, Kugler E, et al. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. Am J Hematol. 2014; 89: 243-248.
33. Eguchi K, Shinkai T, Sasaki Y, et al. Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Jpn J Cancer Res. 1990; 81: 1168-1174.
34. Interleukin 2. [webpage on the Internet] Available from: http://en. wikipedia. org/wiki/Interleukin_2. [updated 2015 January 26]. Accessed March 29, 2015.
35. Geertsen PF, Gore ME, Negrier S, Tourani JM, von der Maase H. Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinoma. Br J Cancer. 2004; 90: 1156-1162.
36. López-Jiménez J, Pérez-Oteyza J, Munoz A, et al. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study. Bone Marrow Transplant. 1997; 19: 429-434.
37. Gerth WC, Betschel SD, Zbrozek AS. Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada. Allergy Asthma Clin Immunol. 2014; 10: 23.
38. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013; 23: 55-60.
39. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012; 32: 1180-1192.
40. Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol. 2013; 131: e1-e3.
41. Kittner JM, Grimbacher B, Wulff W, Jäger B, Schmidt RE. Patients' attitude to subcutaneous immunoglobulin substitution as home therapy. J Clin Immunol. 2006; 26: 400-405.
42. Gardulf A, Björvell H, Andersen V, et al. Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs. 1995; 21: 917-927.
43. Wasserman RL, Melamed I, Stein MR, et al; IGSC, 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012; 130: 951. e-957. e.
44. Bodur HA, Saygili F, Saygili S, Doganay LH, Yesil S. Continuous infusion of subcutaneous compared to intravenous insulin for tight glycaemic control in medical intensive care unit patients. Anaesth Intensive Care. 2008; 36: 520-527.
45. Neff K, Donegan D, MacMahon J, et al. Management of parenteral nutrition associated hyperglycaemia: a comparison of subcutaneous and intravenous insulin regimen. Ir Med J. 2014; 107: 141-143.
46. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999; 67: 352-360.
47. Pezzarossa A, Taddei F, Cimicchi MC, et al. Perioperative management of diabetic subjects. Subcutaneous versus intravenous insulin administration during glucose-potassium infusion. Diabetes Care. 1988; 11: 52-58.
48. Wazny LD, Raymond CB, Sood AR, Eng A, Verrelli M. Cost analysis of an intravenous to subcutaneous epoetin α conversion. Am J Nephrol. 2013; 38: 496-500.
49. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40: 439-446.
50. Albitar S, Meulders Q, Hammoud H, Soutif C, Bouvier P, Pollini J. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant. 1995; 10(suppl 6): 40-43.
51. McFarlane PA, Hillmer MP, Dacouris N. A change from subcutaneous to intravenous erythropoietin increases the cost of anemia therapy. Nephron Clin Pract. 2007; 107: c90-c96.
52. Vercaigne LM, Collins DM, Penner SB. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population. J Clin Pharmacol. 2005; 45: 895-900.
53. Raymond CB, Collins DM, Bernstein KN, Skwarchuk DE, Vercaigne LM. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration. Nephron Clin Pract. 2006; 102: c88-c92.
54. Galliford JW, Malasana R, Farrington K. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant. 2005; 20: 1956-1962.
55. Robinson AM, McLean KA, Greaves M, Channer KS. Subcutaneous versus intravenous administration of heparin in the treatment of deep vein thrombosis; which do patients prefer? A randomized cross-over study. Postgrad Med J. 1993; 69: 115-116.
56. Barber ND, Hoffmeyer UK. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis. Ann R Coll Surg Engl. 1993; 75: 430-433.
57. Honarmand A, Safavi M, Karaky H. Preincisional administration of intravenous or subcutaneous infiltration of low-dose ketamine suppresses postoperative pain after appendectomy. J Pain Res. 2012; 5: 1-6.
58. Javid MJ, Rahimi M, Keshvari A. Dissociative conscious sedation, an alternative to general anesthesia for laparoscopic peritoneal dialysis catheter implantation: a randomized trial comparing intravenous and subcutaneous ketamine. Perit Dial Int. 2011; 31: 308-314.
59. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med. 1999; 159: 2721-2724.
60. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999; 83(286-288): A6-A7.
61. Gauthier D, Schambach S, Crouzet J, Sirvain S, Fraisse T. Subcutaneous and intravenous ceftriaxone administration in patients more than 75 years of age. Med Mal Infect. 2014; 44: 275-280.
62. Harb G, Lebel F, Battikha J, Thackara JW. Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers. Curr Med Res Opin. 2010; 26: 279-288.
63. Daoust R, Paquet J, Lavigne G, Piette É, Chauny JM. Impact of age, sex and route of administration on adverse events after opioid treatment in the emergency department: a retrospective study. Pain Res Manag. 2015; 20: 23-28.
64. Walsh D, Perin ML, McIver B. Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use. Am J Hosp Palliat Care. 2006; 23: 353-359.
65. Campbell RL, Bellolio MF, Knutson BD, et al. Epinephrine in anaphylaxis: higher risk of cardiovascular complications and overdose after administration of intravenous bolus epinephrine compared with intramuscular epinephrine. J Allergy Clin Immunol Pract. 2015; 3: 76-80.
66. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant. 2003; 17: 254-258.
67. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl. 2003; 9: 182-187.
68. Franciosi M, Caccamo L, De Simone P, et al; TWINS I Study Group. Development and validation of a questionnaire evaluating the impact of hepatitis B immune globulin prophylaxis on the quality of life of liver transplant recipients. Liver Transpl. 2012; 18: 332-339.
69. Oncaspar. [webpage on the Internet] Available from: http://www. rxlist. com/oncaspar-drug. htm. [updated 2014 May 2]. Accessed March 29, 2015.
70. Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer. 2012; 59: 436-439.
71. Petersen WC Jr, Clark D, Senn SL, et al. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014; 31: 311-317.
72. Milkovich G, Piazza CJ. Considerations in comparing intravenous and intramuscular antibiotics. Chemotherapy. 1991; 37(suppl 2): 1-13.
73. Chin A, Gill MA, Ito MK, et al. A cost comparison of intramuscular versus intravenous imipenem. Hosp Pharm. 1989; 24: 905-909.
74. Radwanski E, Batra V, Cayen M, et al. Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injections. Antimicrob Agents Chemother. 1997; 41: 1794-1796.
75. Antony KK, Lewis EW, Kenny MT, et al. Pharmacokinetics and bioavailability of a new formulation of teicoplanin following intravenous and intramuscular administration to humans. J Pharm Sci. 1991; 80: 605-607.
76. Goonetilleke AK, Dev D, Aziz I, Hughes C, Smith MJ, Basran GS. A comparative analysis of pharmacokinetics of ceftriaxone in serum and pleural fluid in humans: a study of once daily administration by intramuscular and intravenous routes. J Antimicrob Chemother. 1996; 38: 969-976.
77. Momeni M, Esfandbod M, Saeedi M, Farnia M, Basirani R, Zebardast J. Comparison of the effect of intravenous ketamine and intramuscular ketamine for orthopedic procedures in children's sedation. Int J Crit Illn Inj Sci. 2014; 4: 191-194.
78. Ramaswamy P, Babl FE, Deasy C, Sharwood LN. Pediatric procedural sedation with ketamine: time to discharge after intramuscular versus intravenous administration. Acad Emerg Med. 2009; 16: 101-107.
79. Roback MG, Wathen JE, MacKenzie T, Bajaj L. A randomized, controlled trial of i. v. versus i. m. ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. Ann Emerg Med. 2006; 48: 605-612.
80. Dale O, Thoner J, Nilsen T, Tveita T, Borchgrevink PC, Klepstad P. Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. Eur J Clin Pharmacol. 2007; 63: 837-842.
81. Tveita T, Thoner J, Klepstad P, Dale O, Jystad A, Borchgrevink PC. A controlled comparison between single doses of intravenous and intramuscular morphine with respect to analgesic effects and patient safety. Acta Anaesthesiol Scand. 2008; 52: 920-925.
82. Hendrickson M, Myre L, Johnson DG, Matlak ME, Black RE, Sullivan JJ. Postoperative analgesia in children: a prospective study in intermittent intramuscular injection versus continuous intravenous infusion of morphine. J Pediatr Surg. 1990; 25: 185-190.
83. Ellis RM, Sprivulis PC, Jelinek GA, et al. A double-blind, randomized trial of intravenous versus intramuscular antivenom for red-back spider envenoming. Emerg Med Australas. 2005; 17: 152-156.
84. Isbister GK, O'Leary M, Miller M, et al. A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom. Br J Clin Pharmacol. 2008; 65: 139-143.
85. Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol. 1998; 101: 33-37.
86. Haymore BR, Carr WW, Frank WT. Anaphylaxis and epinephrine prescribing patterns in a military hospital: underutilization of the intramuscular route. Allergy Asthma Proc. 2005; 26: 361-365.
87. Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001; 108: 871-873.
88. REBIF. [webpage on the Internet] Available from: http://www. rxlist. com/rebif-drug/indications-dosage. htm. [updated 2014 May 12]. Accessed March 29, 2015.
89. AVONEX®. [webpage on the Internet] Available from: http://www. rxlist. com/avonex-drug/indications-dosage. htm. [updated 2013 March 27]. Accessed March 29, 2015.
90. Guo S, Bozkaya D, Ward A, et al. Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications. Pharmacoeconomics. 2009; 27: 39-53.
91. Calabrese M, Bernardi V, Atzori M, et al. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis. Mult Scler. 2012; 18: 418-424.
92. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence. 2011; 5: 73-84.
93. Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum. 1990; 33: 91-94.
94. Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol. 1993; 20(11): 1845-1849.
95. Arthur V, Jubb R, Homer D. A study of parenteral use of methotrexate in rheumatic conditions. J Clin Nurs. 2002; 11: 256-263.
96. Müller-Ladner U, Rockwitz K, Brandt-Jürgens J, et al; MC-MTX. 10/RH Study Group. Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. Open Rheumatol J. 2010; 4: 15-22.
97. Stelling JR, Chapman ET, Frankfurter D, Harris DH, Oskowitz SP, Reindollar RH. Subcutaneous versus intramuscular administration of human chorionic gonadotropin during an in vitro fertilization cycle. Fertil Steril. 2003; 79: 881-885.
98. Shah DK, Missmer SA, Correia KF, Ginsburg ES. Pharmacokinetics of human chorionic gonadotropin injection in obese and normal-weight women. J Clin Endocrinol Metab. 2014; 99: 1314-1321.
99. Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol. 2010; 9: 166-171.
100. Klein CG, Cicinnati V, Schmidt H, et al. Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study. Ann Transplant. 2013; 18: 677-684.
101. Thürmann PA, Szymanski J, Haffner S, Tenter U, Grieger F, Sonnenburg C. Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. Eur J Clin Pharmacol. 2006; 62: 511-512.
102. Hahner S, Burger-Stritt S, Allolio B. Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol. 2013; 169: 147-154.
103. Cooper IM. Morphine for postoperative analgesia. A comparison of intramuscular and subcutaneous routes of administration. Anaesth Intensive Care. 1996; 24: 574-578.
104. Thomas JR, Yocum RC, Haller MF, Flament J. The INFUSE-morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Symptom Manage. 2009; 38: 673-682.
105. Thomas JR, Wallace MS, Yocum RC, Vaughn DE, Haller MF, Flament J. The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness. J Pain Symptom Manage. 2009; 38: 663-672.
106. Yang H, Heng X, Liang C, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily insulin injections in Chinese patients with type 2 diabetes mellitus. J Int Med Res. 2014; 42: 1002-1010.
107. Calcium gluconate injection. [webpage on the Internet] Available from: http://www. rxlist. com/calcium-gluconate-drug. htm. [updated 2009 April 2]. Accessed May 1, 2015.
108. Promethazine hydrochloride injection. [webpage on the Internet] Available from: http://www. rxlist. com/promethazine-hcl-injection-drug/indications-dosage. htm. [updated 2007 June 21]. Accessed May 1, 2015.
109. Norepinephrine bitartrate injection. [webpage on the Internet] Available from: http://www. rxlist. com/levophed-drug/warnings-precautions. htm. [updated 2012 December 2]. Accessed May 1, 2015.
110. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant. 2000; 15: 2014-2019.
111. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010; 116: 4745-4753.